Peter J Ruane

Author PubWeight™ 10.32^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.	N Engl J Med	2015	3.16
2	Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men.	Clin Infect Dis	2005	1.97
3	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.	N Engl J Med	2015	1.94
4	Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.	AIDS	2007	1.01
5	Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.	Antivir Ther	2010	0.97
6	Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.	HIV Clin Trials	2011	0.93
7	In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates.	Diagn Microbiol Infect Dis	2008	0.76
8	What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1.	AIDS Read	2004	0.75
9	What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.	AIDS Read	2004	0.75